Draft Guidance for Clinical Investigators, Industry, and FDA Staff: Financial Disclosure by Clinical Investigators; Availability
Health and Human Services Department; Food and Drug Administration · 2011
Read Draft Guidance for Clinical Investigators, Industry, and FDA Staff: Financial Disclosure by Clinical Investigators; Availability by Health and Human Services Department; Food and Drug Administration (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/uslaw-fr-2011-12623.txt.
Description
Notice published in the Federal Register on 2011-05-24 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo). [Pages 30175-30176] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2011-12623] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-1999-D-0792] (Formerly FDA-1999-D-0792) Draft Guidance for Clinical Investigators, Industry, and FDA Staff: Financial Disclosure by Clinical Investigators; Availability.
Catalog record
| CREATOR | Health and Human Services Department; Food and Drug Administration |
|---|---|
| YEAR | 2011 |
| COLLECTION | LAW |
| FORMAT | TXT |
| FILE SIZE | 8 KB |
| VERSION | 1.0 |
| LICENSE | Public Domain |
| RIGHTS | PUBLIC DOMAIN |
| SOURCE | Federal Register |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Draft Guidance for Clinical Investigators, Industry, and FDA Staff: Financial Disclosure by Clinical Investigators; Availability
Citation: us:fr:2011-12623
Creator: Health and Human Services Department; Food and Drug Administration
Year: 2011
Source-URL: https://www.federalregister.gov/documents/2011/05/24/2011-12623/draft-guidance-for-clinical-investigators-industry-and-fda-staff-financial-disclosure-by-clinical
Context: Notice published in the Federal Register on 2011-05-24 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo).
[Pages 30175-30176]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-12623]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-1999-D-0792] (Formerly FDA-1999-D-0792)
Draft Guidance for Clinical Investigators, Industry, and FDA
Staff: Financial Disclosure by Clinical Investigators; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a draft guidance entitled ``Guidance for Clinical
Investigators, Industry, and FDA Staff: Financial Disclosure by
Clinical Investigators.'' This draft guidance is intended to assist
clinical investigators, industry, and FDA staff in interpreting and
complying with the regulations governing financial disclosure by
clinical investigators. This guidance provides FDA's responses to the
most frequently asked questions regarding financial disclosure by
clinical investigators.
DATES: Although comments on any guidance can be submitted at any time
(see 21 CFR 10.115(g)(5)), to ensure that the Agency considers a
comment on this draft guidance before it begins work on the final
version of the guidance, electronic or written comments on the draft
guidance should be submitted by July 25, 2011. Submit written comments
on the draft guidance to the Division of Dockets Management (HFA-305),
Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville,
MD 20852. Submit electronic comments to http://www.regulations.gov. See
the SUPPLEMENTARY INFORMATION section for electronic access to the
draft guidance document.
ADDRESSES: Submit written requests for single copies of this draft
guidance to the Division of Drug Information, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 2201, Silver Spring, MD 20993-0002 (1-
888-463-6332 or 301-796-3400); or the Office of Communication, Outreach
and Development (HFM-40), Center for Biologics Evaluation and Research,
Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-
1448 (1-800-835-4709 or 301-827-1800); or the Division of Small
Manufacturers, International, and Consumer Assistance, Center for
Devices and Radiological Health, Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 66, rm. 4622, Silver Spring, MD 20993 (1-800-
638-2041 or 301-796-7100). Send one self-addressed adhesive label to
assist the office in processing your requests.
Submit electronic comments on the draft guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Marsha Melvin, Office of Good
Clinical Practice, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 32, rm. 5170, Silver Spring, MD 20993-0002, 301-796-8345.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of a draft guidance entitled
``Guidance for Clinical Investigators, Industry, and FDA Staff:
Financial Disclosure by Clinical Investigators.'' This guidance is
intended to assist clinical investigators, industry, and FDA staff in
interpreting and complying with the regulations governing financial
disclosure by clinical investigators, part 54 (21 CFR part 54), and to
provide FDA's responses to the most frequently asked questions
regarding financial disclosure by clinical investigators. When
finalized, this guidance will supersede ``Guidance for Industry--
Financial Disclosure by Clinical Investigators'' (March 20, 2001,
Center for Drug Evaluation and Research, Center for Biologics
Evaluation and Research, and Center for Devices and Radiological
Health).
This guidance also responds to recommendations made by the Office
of the Inspector General (OIG), Department of Health and Human
Services, in their report entitled ``The Food and Drug Administration's
Oversight of Clinical Investigators' Financial Information.'' \1\ The
OIG's recommendations were intended to strengthen FDA's oversight
[[Page 30176]]
and review of clinical investigators' financial disclosures.
Specifically, the draft guidance will describe: (1) The sponsor's
responsibility to collect the financial disclosure information prior to
an investigator participating in a study and ensure that all required
forms and attachments are submitted in marketing applications; (2) what
is meant by ``due diligence'' in obtaining financial disclosures from
investigators; and (3) how FDA will review financial disclosure
information. The guidance will also seek comment on the circumstances
under which FDA should consider public release of financial disclosure
information related to an approved marketing application.
---------------------------------------------------------------------------
\1\ OIG report OEI-05-07-00730 available at http://oig.hhs.gov/oei/reports/oei-05-07-00730.pdf. (FDA has verified the Web site
address, but FDA is not responsible for any subsequent changes to
the Web site after this document publishes in the Federal Register.)
---------------------------------------------------------------------------
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the Agency's current thinking on this topic.
It does not create or confer any rights for or on any person and does
not operate to bind FDA or the public. An alternative approach may be
used if such approach satisfies the requirements of the applicable
statutes and regulations.
II. The Paperwork Reduction Act of 1995
This draft guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in part 54 and 21 CFR parts 312 and 812 have
been approved under OMB control number 0910-0396; OMB control number
0910-0014; and OMB control number 0910-0078.
III. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) electronic or written comments regarding this draft
guidance document. It is no longer necessary to send two copies of
mailed comments. Identify comments with the docket number found in
brackets in the heading of this document. Received comments may be seen
in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday.
IV. Electronic Access
Persons with access to the Internet may obtain the document at
http://www.regulations.gov or http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ProposedRegulationsandDraftGuidances/default.htm.
Dated: May 16, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-12623 Filed 5-23-11; 8:45 am]